GlobeNewswire

Mandalay Resources Drills Multiple High-Grade Intercepts Beneath Historic Costerfield Mine, Victoria, Australia

Dela

TORONTO, April 03, 2018 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation ("Mandalay" or the "Company") (TSX:MND) is pleased to provide results from recent diamond drilling at its Costerfield Operations in Victoria, Australia.

This press release refers to tables and figures. The accompanying Table 2 can be found at the end of this press release, whereas the accompanying Figures 1, 2 and 3 can be found in an exploration presentation posted on the Company's website at the following address: http://www.mandalayresources.com/investor-presentations/#Technical_Presentations

Mandalay's recent and ongoing exploration drilling campaign on the property targets projections of veins beneath the historic Kendall and Costerfield mine, which was the largest historical producer in the district from 1864 to 1938 (Figure 1). Resulting intercepts demonstrate gold-antimony mineralization along a strike length of approximately 600 m and a dip length of approximately 200 m (Figures 2 and 3).

Highlights from drilling include the following six intercepts, which delineate a high-grade core of mineralization along the Costerfield Deeps projection measuring approximately 400 in strike by 150 m down-dip. The Company has named this emerging shoot the Youle vein after one of the three original prospectors in the district.

Table 1: Highlights of drill intercepts on the Youle Vein

Hole True Width 
(m)
Gold
(g/t)
Sb
(%)
AuEq (g/t) over
min. 1.8 m
mining width
BC021A 0.58   272.1 13.3 94.7
BC011 3.50 14.7 10.9 65.9
BC015 0.37   120.9 11.1 28.6
BC006W1 0.57 59.8   3.2 20.5
BC019 0.18 16.2   55.8 11.4
BC002 0.15 76.4   33.3 11.3

*Using metal prices of $1,400/oz Au and $10,000/t Sb
- AuEq(g/t) = Au(g) + Sb(%) x (Price per 10 Sb(kg) × Sb Recovery(%) )/(Price per 1 Au(g) × Au Recovery (%))

Mark Sander, President and Chief Executive Officer of Mandalay commented, "We are encouraged by the high-grade cluster of drill intercepts defining the core of the emerging Youle vein beneath the historic Costerfield mine. This setting is similar to the locations of the Augusta Lodes, the Cuffley Lode and the Brunswick Lode beneath other historic mines of the district, all of which Mandalay has converted to Mineral Reserves and has either mined or is preparing to mine.

"The drill hole intercepts of Youle reported in this press release contain some extraordinary gold and antimony grades that dilute to potentially minable gold equivalent grades over our minimum mining width of 1.8 m. As well, the strike length (400-600 m) and depth extent (150-200 m) of the intercepts are entirely consistent with the dimensions of orebodies we have found beneath the other historic mines in the district that have proved very profitable for Mandalay."   

Mr. Sander concluded, "There is room to grow this discovery along strike and down dip. The fact that Youle lies just several hundred metres to one kilometre from the Brunswick Lode, to which capital development access will be created later this quarter, suggests that there is potential to access the shoot quickly and for limited development capital. We plan to add additional surface rigs to the Youle drilling program to expand and infill high-grade mineralization as quickly as possible, with the goal of adding significantly to the Company's Mineral Resources and Reserves by the end of 2018."

Youle Drill Campaign History

Mandalay has drilled 27 diamond holes into the historic Costerfield mine area in three campaigns (2011, 2014 and 2017-2018). The Company reported significant early results from the Youle drill program in July, 2017 (see Mandalay July 24, 2017, press release).  Drilling accelerated in late 2017 after it was clear that Mandalay would commit to developing the Brunswick Lode, which will halve the distance to access Youle from then-limits of mining at Cuffley, and after significant advances were made in the understanding of the local mineralization. This program continued into 2018 with new results reported here leading to preliminary interpretation of Youle mineralization as a downward offset of the historically mined Costerfield Lode (Figures 2 and 3).

Drilling and Assaying

Diamond drill core was logged and sampled by Costerfield geologists. All samples were sent to Onsite Laboratory in Bendigo, Victoria, Australia, for sample preparation and assay. Site geological and metallurgical personnel have implemented a QA/QC process that includes the regular submission of standard reference materials and blanks with drill and face samples submitted for assay.  Standard reference materials have been certified by Geostats Pty Ltd. (see March 29, 2018, Technical Report entitled "Costerfield Operation, Victoria, Australia NI 43-101 Report", available on SEDAR (www.sedar.com), which contains a complete description of drilling, sampling, and assaying procedures.)

Table 2: Significant Drill Intercepts at Youle

Hole ID Hole
Completion
Date
Total
hole 
Depth
Intercept 
Easting 
(Mine 
Grid)
Intercept 
Northing 
(Mine
Grid)
Intercept
Elevation 
(Mine
Grid)
Drilled
Width
(m)
True
Width
(m)
Au 
Grade
(g/t)
Sb 
Grade
(%)
AuEq
(g/t)
Target
BC018 26/02/2018 402.0 15353 6523 1022 0.16 0.16 0.5 7.8 14.3 Youle Parallel Mineralization
BC017 14/02/2018 330.0 15339 6556 980 0.10 0.10 0.3 4.3 7.9 Youle
MB011 24/10/2011 480.0 15375 6629 914 0.07 0.06 130.9 44.6 209.4 Youle
MB011 24/10/2011 480.0 15369 6631 923 0.14 0.12 30.8 18.7 63.7 Youle Parallel Mineralization
BC001 8/07/2014 394.2 15399 6650 1007 0.10 0.07 3.1 0.8 4.5 Youle
BC013 23/01/2018 420.3 15326 6703 880 0.14 0.12 0.4 0.0 0.4 Youle
BC019 14/03/2018 386.9 15399 6745 952 0.18 0.18 16.2 55.8 114.4 Youle
BC007W1 5/06/2017 821.3 15235 6778 798 0.10 0.09 3.4 6.0 14.0 Youle
BC016 19/03/2018 401.7 15329 6786 854 0.21 0.17 9.6 14.3 34.8 Youle
BC002 18/06/2014 464.7 15372 6837 909 0.17 0.15 76.4 33.3 135.0 Youle
BC015 7/03/2018 431.7 15340 6925 834 0.47 0.37 120.9 11.1 140.4 Youle
BC006W1 29/06/2017 720.0 15362 6979 828 1.01 0.57 59.8 3.2 65.4 Youle
BC021A 21/03/2018 374.7 15408 6980 891 0.61 0.58 272.1 13.3 295.5 Youle
MB012 29/11/2011 475.3 15409 7047 895 0.15 0.10 94.1 19.3 128.1 Youle
BC010 3/01/2018 330.9 15450 7054 1002 0.19 0.10 6.8 13.7 31.0 Kendall West
BC010 3/01/2018 330.9 15445 7054 1008 0.27 0.14 21.1 12.5 43.1 Kendall West
BC011 17/01/2018 450.1 15394 7094 828 1.70 0.58 60.6 53.1 154.0 Youle
BC011* 17/01/2018 450.1 15394 7094 828 10.24 3.50 14.7 10.9 33.9 Youle Extended Composite
BC011W2 6/02/2018 395.7 15410 7126 858 0.32 0.08 9.1 5.4 18.6 Youle
BC014 7/03/2018 500.6 15373 7185 789 1.17 0.64 2.5 1.5 5.2 Youle West Splay
BC014 7/03/2018 500.6 15378 7185 756 0.23 0.15 0.3 1.0 1.9 Youle
BC014W1 19/01/2018 389.4 15384 7189 846 0.92 0.64 0.6 0.8 2.0 Youle West Splay
BC014W1 19/01/2018 389.4 15400 7191 810 0.11 0.10 0.7 7.4 13.7 Youle West Splay

Notes:
* Inclusive of other BC011 intercept.
- Using metal prices of $1,400/oz Au and $10,000/t Sb
- True width is preliminary estimate only and may not reflect final true width used in resource
- AuEq(g/t) = Au(g) + Sb(%) x (Price per 10 Sb(kg) × Sb Recovery(%) )/(Price per 1 Au(g) × Au Recovery (%))

Qualified Person:

Chris Gregory, Vice President of Operational Geology and Exploration at Mandalay Resources, is a Member of the Australian Institute of Geoscientists (AIG), and a Qualified Person as defined by NI 43-101. He has reviewed and approved the technical and scientific information provided in this release.

For Further Information:

Mark Sander
President and Chief Executive Officer

Greg DiTomaso
Director of Investor Relations

Contact: 647.260.1566

About Mandalay Resources Corporation:

Mandalay Resources is a Canadian-based natural resource company with producing assets in Australia and Sweden, and care and maintenance and development projects in Chile. The Company is focused on executing a roll-up strategy, creating critical mass by aggregating advanced or in production gold, copper, silver and antimony projects in Australia, the Americas and Europe to generate near-term cash flow and shareholder value.

Forward-Looking Statements:

This news release contains "forward-looking statements" within the meaning of applicable securities laws. Readers are cautioned not to place undue reliance on forward-looking statements. Actual results and developments may differ materially from those contemplated by these statements depending on, among other things, changes in commodity prices and general market and economic conditions. The factors identified above are not intended to represent a complete list of the factors that could affect Mandalay. A description of additional risks that could result in actual results and developments differing from those contemplated by forward-looking statements in this news release can be found under the heading "Risk Factors" in Mandalay's annual information form dated March 29, 2018, a copy of which is available under Mandalay's profile at www.sedar.com. In addition, there can be no assurance that any inferred resources that are discovered as a result of additional drilling will ever be upgraded to proven or probable reserves. Although Mandalay has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Mandalay Resources Corporation via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum